ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0189

“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists

Megan Creasman1, Jing Li2, Augusto Garcia-Agundez3, gabriela Schmajuk4 and Jinoos Yazdany3, 1UC San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, San Francisco, CA, 4University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0175–0198) Health Services Research Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Heavy documentation contributes to clinician workload and burnout. Rheumatology carries one of the highest documentation burdens among Internal Medicine (IM) subspecialties. While recent advances in artificial intelligence (AI) have led to the development of AI scribes that can produce structured clinical notes in real time, little is known about how rheumatologists use these tools. The implementation of AI scribes across a large ambulatory academic health system provided a unique opportunity to compare the adoption, retention, and utilization patterns of AI scribes by rheumatologists compared to other physicians.

Methods: Data from Dec 2024-May 2025 was collected to capture AI scribes use. Ambulatory physicians were eligible to access AI scribes and became “live users” after completing a training; live users became “active users” if they used AI scribes at least once in the preceding 30 days. Provider adoption was defined as the ratio of live users to all eligible providers. Retention was defined as the ratio of active to live users in the preceding 30 days. To assess utilization, live users were categorized based on the percentage of eligible encounters that used AI scribes in the past 30 days: low (< 30%), medium (30–70%), and high ( >70%). Fisher’s exact test was used to compare the proportion of high utilizers between rheumatology vs. IM physicians and rheumatology vs. non-IM physicians. Outcome measures tracked the average weekly time spent on EHR activities per provider, comparing the 90 days prior to the date each physician became a “live user” to the post AI scribes period.

Results: 2477 physicians were eligible to start using AI scribes; by the end of the observation period 888 (37%) had become live users. Adoption by rheumatologists was 41% (12/29) compared to 49% for all other IM physicians (224/455, 15 specialties). Of IM sub-specialties Rheumatology was 10th by adoption rate. Among rheumatologists, retention was 100%, slightly higher than the 94% retention seen across IM. Rheumatology live users used AI scribes for more of their encounters (78%) than any other IM specialty (62%) and non-IM physicians (55%; see Figure 1). Rheumatology had the largest percentage of high utilizers of all IM specialties (83% vs. 52%; see Figure 2). By Fisher’s exact test Rheumatology had a numerically higher but not statistically significant proportion of high utilizers than IM (83% vs. 72%, p=0.5) and a significantly higher proportion than non-IM physicians (83% vs. 42%, p=0.006). Live users from IM specialties and rheumatology decreased mean time spent in all EHR activities, documentation, work outside of work, and patient instructions; rheumatologists had slightly less time savings except in patient instructions (see Figure 3).

Conclusion: Approximately half of rheumatologists adopted AI scribes, emerging as the highest users per encounter among IM subspecialties. Retention was consistently high across all specialties, including rheumatology, underscoring sustained engagement. Rheumatologists enjoyed time savings across all four outcome measures. Future research should investigate the implications of AI scribes on rheumatologist well-being and the patient experience.

Supporting image 1Figure 1. Visit Utilization in in Rheumatology, IM and Non-IM Specialties

Supporting image 2Figure 2. Top Five IM Specialties by Provider Visit Utilization

Supporting image 3Figure 3. Outcomes by IM Specialty


Disclosures: M. Creasman: None; J. Li: None; A. Garcia-Agundez: None; g. Schmajuk: None; J. Yazdany: AstraZeneca, 2, 5, Aurinia, 5, BMS Foundation, 5, 12, BMS Foundation, Gilead, 5, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

Creasman M, Li J, Garcia-Agundez A, Schmajuk g, Yazdany J. “Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/try-it-youll-love-it-patterns-of-ai-scribes-use-among-rheumatologists/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/try-it-youll-love-it-patterns-of-ai-scribes-use-among-rheumatologists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology